Tumor Banking for the Southwest Oncology Group

西南肿瘤学组的肿瘤库

• 批准号: 8322264
• 负责人: LAURENCE HOWARD BAKER
• 金额: $ 12.45万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-25 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8322264
• 关键词: Address; Applications Grants; Cancer Intervention; Cessation of life; Clinical; Clinical Treatment; Clinical Trials; Collection; Critical Pathways; Data; Development; Diagnosis; Disease; Ensure; Funding; Generations; Goals; Human; Individual; Institution; Laboratories; Malignant Neoplasms; Marketing; Molecular; Nucleic Acids; Outcome; Pathologist; Patient Representative; Patients; Phase III Clinical Trials; Policies; Population Group; Population Heterogeneity; Prediction of Response to Therapy; Procedures; Process; Recurrence; Research; Research Infrastructure; Research Personnel; Resistance; Science; Serum; Solid Neoplasm; Southwest Oncology Group; Specimen; Staging; Structure; Technology; Testing; Tissues; Tumor Bank; Work; base; cancer initiation; data sharing; improved; insight; multidisciplinary; novel diagnostics; novel therapeutics; operation; patient population; prognostic; prospective; randomized trial; response; sample collection; statistical center; therapeutic target; tool; tumor; tumor progression

DESCRIPTION (provided by applicant): This application is being prepared by the Southwest Oncology Group (SWOG) in response to the NCI-issued RFA to provide and enhance the infrastructure needed to ensure the collection of, storage of and access to high-quality, well-annotated human specimens collected from and representative of the patient populations entered into NCI-funded clinical trials. The advent of powerful molecular technologies and the emergence of targeted therapeutics have opened the door to developing more effective and in some cases, individualized treatments of patients with cancer. Access to specimens with associated high-quality clinical, treatment, recurrence and outcome data is critical to developing and validating the tests needed for diagnosis, target identification and prediction of response to therapy. Developing and effectively utilizing cancer interventions based on the comprehensive analysis of critical pathways of cancer initiation and progression require access to biospecimens from patients treated in prospective randomized trials. High quality banks of uniformly collected specimens with validated clinical and outcome data are essential for the development and delivery o new diagnostic and predictive tools that are critical to eliminating the suffering and death due to cancer. Together with the various Disease and Correlative Science Committees and their clinical trials, we are developing multiple approaches to the collection and analysis of tumor-related biospecimens. Specific Aim 1: To provide high quality, well-annotated tissues and other biospecimens collected from and representative of the patients entered in NCI-sponsored clinical trials for research purposes. Specific Aim 2: To provide information about the specimen collections for potential research use. Specific Aim 3: To increase access to SWOG trial-related biospecimens based on specimen availability and the scientific merit of applications to use the specimens. Specific Aim 4: To work with the NCI and the other cooperative groups to implement the policies and procedures initiated by the Group Banking Committee (GBC). Specific Aim 5: To share data on both the material that is available in the SWOG biospecimens banks and the major scientific insights generated from the use of the specimens.

描述（由申请人提供）： 本申请由西南肿瘤学组（SWOG）编写，以响应NCI发布的RFA，以提供和加强所需的基础设施，以确保采集、储存和获得高质量、注释良好的人体标本，这些标本是从参加NCI资助的临床试验的患者人群中采集的，并代表这些患者人群。强大的分子技术的出现和靶向治疗的出现为开发更有效的癌症患者治疗方法打开了大门，在某些情况下，个性化治疗。获得相关高质量临床、治疗、复发和结局数据的标本对于开发和验证诊断、靶点识别和预测治疗反应所需的检测至关重要。基于对癌症发生和进展的关键途径的综合分析，开发和有效利用癌症干预措施需要获得前瞻性随机试验中接受治疗的患者的生物标本。统一收集的高质量样本库以及经过验证的临床和结果数据对于开发和交付新的诊断和预测工具至关重要，这些工具对于消除癌症造成的痛苦和死亡至关重要。与各种疾病和相关科学委员会及其临床试验一起，我们正在开发多种方法来收集和分析肿瘤相关生物标本。 具体目标1：提供高质量、注释良好的组织和其他生物标本，这些标本是从参加NCI申办的临床试验的患者中采集的，并具有代表性，用于研究目的。 具体目标2：提供有关标本收集的信息，以供潜在的研究使用。 具体目标3：根据标本可用性和标本使用申请的科学价值，增加SWOG试验相关生物标本的获取。 具体目标4：与NCI和其他合作小组合作，执行集团银行委员会（GBC）制定的政策和程序。 具体目标五：分享SWOG生物标本库中可用材料的数据以及使用标本产生的主要科学见解。